StockNews.AI
TXG
StockNews.AI
177 days

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

1. 10x Genomics unveils new single cell and spatial biology innovations. Enhancements support high-performance research. 2. A robust 2025 roadmap extends the Visium and Xenium portfolios. Upgraded resolution and efficiency strengthen the lead. 3. Innovations aim to democratize large-scale single cell analysis. They promise lower costs and greater accessibility. 4. A live workshop at AGBT showcases the latest data and development directions. The event may boost investor confidence in TXG.

8m saved
Insight
Article

FAQ

Why Bullish?

The announcement of groundbreaking products and an ambitious roadmap is likely to drive increased investor optimism. Historically, tech leaders unveiling innovative solutions, like previous TXG product launches, have seen share price improvements.

How important is it?

The extensive product roadmap and technical advancements signal significant future revenue and market share gains for TXG. This news is pivotal for long-term investor confidence and competitive positioning.

Why Long Term?

The strategic enhancements and extended product portfolio promise sustained market leadership. Similar long-term growth trends were observed when past innovations catalyzed industry shifts.

Related Companies

ILMN
New single cell and spatial innovations extend 10x Genomics' technology and performanceleadership across all three platforms PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale. In addition, the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology. "After a record year of innovation, we continue to push the boundaries of what's possible in single cell and spatial biology, taking on the hardest challenges so researchers can make the biggest impact," said Ben Hindson, Co-Founder and Chief Scientific Officer of 10x Genomics. "Our 2025 roadmap will once again raise the bar for the field and enable researchers to tackle bigger questions, analyze more samples and extract deeper insights from their data." 10x Genomics will host a workshop at AGBT today, Sunday, February 23, at 1 p.m. ET to share the latest data and development directions across its three platforms. This workshop will be live-streamed beginning at 1:30 p.m. ET for researchers not attending AGBT. Advancing Large-Scale Single Cell Research Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use. Highlights of 10x's forthcoming innovations in single cell analysis include: Once launched, these offerings will join a broad portfolio of recent Chromium innovations intended to democratize access to single cell analysis by delivering high performance and low cost at any scale. These include: Expanding Technology Leadership in Spatial Biology 10x Genomics continues to lead the spatial biology revolution with a broad portfolio of easy-to-use technologies that enable superior performance and provide deeper, high resolution insights into tissue organization and function. Visium Platform In 2024, 10x Genomics launched its groundbreaking Visium HD product, increasing the resolution of the Visium platform by over three orders of magnitude. Now compatible with FFPE, Fresh Frozen and Fixed Frozen tissues, Visium HD delivers high sensitivity and sequencing efficiency with the proven CytAssist-enabled workflow. 10x Genomics revealed today several planned additions to the Visium HD platform, including: Xenium Platform Throughout AGBT, 10x Genomics will host a series of scientific presentations and events to showcase how its latest technologies are driving biological discovery: About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X (Twitter), Facebook, Bluesky or YouTube. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s ("10x Genomics") product launches, performance, scale, configuration, costs, capabilities, adoption and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release. Disclosure Information10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. ContactsInvestors: [email protected]Media: [email protected] SOURCE 10x Genomics, Inc.

Related News